Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 03, 2022 09:00 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus Expands Executive Leadership Team with the Appointment of José Trevejo, M.D., Ph.D., as Chief Medical Officer

Dr. Trevejo brings over 20 years of clinical development experience to Tarsus as it advances development of TP-03, the first potential treatment for Demodex blepharitis, and its pipeline programs ...
February 02, 2022 16:30 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus to Host Eye Care Leaders Webcast on Unmet Needs in Demodex Blepharitis and Potential of TP-03

Revolutionizing Treatment for Demodex Blepharitis Patients event to feature Eric Donnenfeld, M.D.; Paul Karpecki, O.D.; and Elizabeth Yeu, M.D. Webcast scheduled for Tuesday, February 8, 2022 at 9...
February 02, 2022 07:00 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitis and Secures $175 Million Credit Facility

Topline data expected in April 2022 from Saturn-2, the second Phase 3 pivotal trial of TP-03 and NDA submission remains on track for this year Credit facility with Hercules Capital and Silicon Valley...
January 04, 2022 09:00 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus Appoints Elizabeth Yeu, M.D., a Nationally Recognized Ophthalmologist and Eye Care Leader, to its Board of Directors

Dr. Yeu brings over 20 years of eye care experience, and is a highly regarded leader in clinical care and new product innovation IRVINE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Tarsus...
November 23, 2021 16:30 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus to Participate at Upcoming Virtual Investor Conferences

IRVINE, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
November 10, 2021 16:30 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus to Participate in the Virtual Jefferies London Healthcare Conference 2021

IRVINE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
November 09, 2021 16:05 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus Pharmaceuticals, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Achievements

On track to complete enrollment in the fourth quarter of 2021 for the Saturn-2 Phase 3, the second pivotal trial of TP-03 for the treatment of Demodex blepharitis; topline data expected in the first...
November 04, 2021 09:45 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus Pharmaceuticals, Inc. Presents Data from Two Pioneering Studies on the Prevalence and Impact of Demodex Blepharitis at the American Academy of Optometry 2021 Annual Meeting

Titan real-world prevalence study data reveals that Demodex blepharitis accounts for over two-thirds of all blepharitis cases and is highly prevalent in many commonly seen patient groups New Titan...
November 02, 2021 17:00 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus to Participate in the Virtual Credit Suisse 30th Annual Healthcare Conference

IRVINE, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
August 12, 2021 09:00 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus Pharmaceuticals, Inc. Appoints Pharmaceutical and Healthcare Industry Leader Rosemary A. Crane to Board of Directors

Ms. Crane brings over 30 years of experience in executive leadership, commercialization, and business development in the pharmaceutical and healthcare industries IRVINE, Calif., Aug. 12, 2021 ...